TScan Therapeutics (TCRX) Registration Filing summary

Company overview and business model

• Clinical-stage biotechnology company developing TCR-engineered T cell therapies for cancer patients, with lead candidates in hematologic malignancies and solid tumors.

• Expanding ImmunoBank repository to provide multiplex TCR-T therapies for diverse cancers and HLA types.

• Incorporated in Delaware in 2018, with principal offices in Waltham, MA.

• Qualifies as an emerging growth and smaller reporting company, allowing reduced disclosure requirements until at least December 31, 2026.

Use of proceeds and capital allocation

• Net proceeds intended primarily for research and development, including clinical trials, process development, and manufacturing.

• May also be used for acquisitions or investments in complementary businesses, products, or technologies, as well as for working capital and general corporate purposes.

• Pending use, proceeds may be invested in short-term U.S. Treasury securities or held as cash.

• Management retains broad discretion over allocation of net proceeds.

Risk factors and disclosures

• Investment involves a high degree of risk, including potential adverse effects on business, financial condition, and results of operations.

• Risks include clinical, regulatory, manufacturing, competitive, and macroeconomic uncertainties, as well as reliance on third parties and intellectual property protection.

• Forward-looking statements are subject to known and unknown risks, and actual results may differ materially.